How RWE can help Biotechs optimize the value of their asset
Traditionally, real-world data (RWD) and real-world evidence (RWE) have not been viewed as critical components to be incorporated into the drug development journey to demonstrate value for market access and product launch/commercialization. With the majority of small and emerging biotech companies choosing to seek out partnership or licensing deals to support pivotal trials and ultimately commercialization of their asset, there was little exposure to the numerous benefits RWD and RWE can provide to these companies early in their development planning and execution.
Related Insights
Webinar
Assessing appropriate use of ECAs in clinical trials
May 28, 2023
Webinar
Adaptive strategies for more efficient, data-rich and patient-friendly trials
May 28, 2023
Article
Guide for Real-World Evidence
May 21, 2021
Blog
Integrated evidence planning and RWE: Realizing value throughout the development lifecycle
May 13, 2025
Article
How emerging biotechs can enter the Chinese market and prosper
Jan 18, 2022
Blog
A hybrid model supports globally diverse site participation for a retrospective cancer study
Jul 24, 2023
Video
The science and practice of ethnobridging
May 17, 2023
Playbook
Insights from the 2022 R&D Innovation Survey
Feb 17, 2023
Playbook
Are you using real-world evidence?
Feb 1, 2023
Article
8 things you need to know about eCTDs in China
Jul 1, 2022
Blog
Maintaining Data Integrity for Quality and Compliance – Essential Despite Pandemic Disruptions
May 16, 2022
Article
New FDA Guidance Addresses the Need for Data-Generation Strategies Across the Drug Development Lifecycle
May 10, 2022
Related Insights
Webinar
Assessing appropriate use of ECAs in clinical trials
May 28, 2023
Webinar
Adaptive strategies for more efficient, data-rich and patient-friendly trials
May 28, 2023
Article
Guide for Real-World Evidence
May 21, 2021
Blog
Integrated evidence planning and RWE: Realizing value throughout the development lifecycle
May 13, 2025
Article
How emerging biotechs can enter the Chinese market and prosper
Jan 18, 2022
Blog
A hybrid model supports globally diverse site participation for a retrospective cancer study
Jul 24, 2023
Video
The science and practice of ethnobridging
May 17, 2023
Playbook
Insights from the 2022 R&D Innovation Survey
Feb 17, 2023
Playbook
Are you using real-world evidence?
Feb 1, 2023
Article
8 things you need to know about eCTDs in China
Jul 1, 2022
Blog
Maintaining Data Integrity for Quality and Compliance – Essential Despite Pandemic Disruptions
May 16, 2022
Article
New FDA Guidance Addresses the Need for Data-Generation Strategies Across the Drug Development Lifecycle
May 10, 2022